The prognostic value of micrometastases and isolated tumour cells in histologically negative lymph nodes of patients with colorectal cancer: A systematic review and meta-analysis

详细信息    查看全文

• 作者：D.A.M. Sloothaak ; S. Sahami ; H.J. van der Zaag-Loonen ; E.S. van der Zaag ; P.J. Tanis ; W.A. Bemelman ; C.J. Buskens
• 关键词：Colorectal neoplasm ; Staging ; Occult tumour cells ; Lymph nodes
• 刊名：European Journal of Surgical Oncology (EJSO)
• 出版年：March, 2014
• 年：2014
• 卷：40
• 期：3
• 页码：263-269
• 全文大小：1001 K

文摘

<h4 class="h4">Introductionh4>Detection of occult tumour cells in lymph nodes of patients with stage I/II colorectal cancer is associated with decreased survival. However, according to recent guidelines, occult tumour cells should be categorised in micrometastases (MMs) and isolated tumour cells (ITCs). This meta-analysis evaluates the prognostic value of MMs and of ITCs, separately.<h4 class="h4">Methodsh4>

PubMed, Embase, Biosis and the World Health Organization International Trials Registry Platform were searched for papers published until April 2013. Studies on the prognostic value of MMs and ITCs in lymph nodes of stage I/II colorectal cancer patients were included. Odds ratios (ORs) for the development of disease recurrence were calculated to analyse the predictive value of MMs and ITCs.<h4 class="h4">Resultsh4>

From five papers, ORs for disease recurrence could be calculated for MMs and ITCs separately. In patients with colorectal cancer, disease recurrence was significantly increased in the presence of MMs in comparison with absent occult tumour cells (OR 5.63; 95%CI 2.4-13.13). This was even more pronounced in patients with colon cancer (OR 7.25 95%CI 1.82-28.97). In contrast, disease recurrence was not increased in the presence of ITCs (OR 1.00 95%CI 0.53-1.88).<h4 class="h4">Conclusionh4>

Patients with stage I/II colorectal cancer and MMs have a worse prognosis than patients without occult tumour cells. However, ITCs do not have a predictive value. The distinction between ITCs and MMs should be made if the detection of occult tumour cells is incorporated in the clinical decision for adjuvant treatment.